Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer
- Registry ID
- EUCTR2009-014279-37
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Roche Products Limited
- Start date
- 2009-10-29
- Completion date
- 2015-11-27
- Last update
- 2026-08-16
Conditions
- Advanced triple negative breast cancer
Summary
Tolerability and safety profile of bevacizumab when combined with weekly paclitaxel as first line treatment of metastatic triple negative breast cancer.
Locations
View on source registry